Clinical Trial Update: Demonstrate Noninferiority in Efficacy and to Assess Safety of CT-P13 in Patients With Active Crohn's Disease [Phase 3]

View source ↗

Summary

A Phase 3 trial of CT-P13 (infliximab-dyyb), a biosimilar to infliximab, in active Crohn's disease demonstrated noninferiority in efficacy and included safety a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• CT-P13 (infliximab biosimilar)

Snippet

Sponsor: Celltrion | Conditions: Crohn's Disease | Phase 3 | Status: COMPLETED | Results posted: 2018-04-11